BACKGROUND: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD. METHODS: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako. RESULTS: Single isolates representing 42 of 67 emm-types, accounting for 85% of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50%) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60% of the total emm-types recovered in Bamako, which accounted for 81% of all infections. CONCLUSIONS: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.
BACKGROUND: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD. METHODS: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako. RESULTS: Single isolates representing 42 of 67 emm-types, accounting for 85% of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50%) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60% of the total emm-types recovered in Bamako, which accounted for 81% of all infections. CONCLUSIONS: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.
Authors: Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale Journal: Infect Immun Date: 2002-04 Impact factor: 3.441
Authors: Eloi Marijon; Phalla Ou; David S Celermajer; Beatriz Ferreira; Ana Olga Mocumbi; Dinesh Jani; Christophe Paquet; Sophie Jacob; Daniel Sidi; Xavier Jouven Journal: N Engl J Med Date: 2007-08-02 Impact factor: 91.245
Authors: Shelly A McNeil; Scott A Halperin; Joanne M Langley; Bruce Smith; Andrew Warren; Geoffrey P Sharratt; Darlene M Baxendale; Mark A Reddish; Mary C Hu; Steven D Stroop; Janine Linden; Louis F Fries; Peter E Vink; James B Dale Journal: Clin Infect Dis Date: 2005-09-12 Impact factor: 9.079
Authors: James B Dale; Vincent A Fischetti; Jonathan R Carapetis; Andrew C Steer; Samba Sow; Rajesh Kumar; Bongani M Mayosi; Fran A Rubin; Kim Mulholland; Joachim Maria Hombach; Florian Schödel; Ana Maria Henao-Restrepo Journal: Vaccine Date: 2013-04-18 Impact factor: 3.641
Authors: Rosalyn E O'Loughlin; Angela Roberson; Paul R Cieslak; Ruth Lynfield; Ken Gershman; Allen Craig; Bernadette A Albanese; Monica M Farley; Nancy L Barrett; Nancy L Spina; Bernard Beall; Lee H Harrison; Arthur Reingold; Chris Van Beneden Journal: Clin Infect Dis Date: 2007-08-29 Impact factor: 9.079
Authors: F Koutouzi; A Tsakris; P Chatzichristou; E Koutouzis; G L Daikos; E Kirikou; N Petropoulou; V Syriopoulou; A Michos Journal: J Clin Microbiol Date: 2015-04-15 Impact factor: 5.948
Authors: George E Nelson; Tracy Pondo; Karrie-Ann Toews; Monica M Farley; Mary Lou Lindegren; Ruth Lynfield; Deborah Aragon; Shelley M Zansky; James P Watt; Paul R Cieslak; Kathy Angeles; Lee H Harrison; Susan Petit; Bernard Beall; Chris A Van Beneden Journal: Clin Infect Dis Date: 2016-04-22 Impact factor: 9.079
Authors: James B Dale; Shannon E Niedermeyer; Tina Agbaosi; Nicholas D Hysmith; Thomas A Penfound; Claudia M Hohn; Matthew Pullen; Michael I Bright; Daniel S Murrell; Lori E Shenep; Harry S Courtney Journal: Clin Vaccine Immunol Date: 2015-01-28
Authors: Deborah A Williamson; Pierre R Smeesters; Andrew C Steer; John D Steemson; Adrian C H Ng; Thomas Proft; John D Fraser; Michael G Baker; Julie Morgan; Philip E Carter; Nicole J Moreland Journal: J Clin Microbiol Date: 2015-08-19 Impact factor: 5.948
Authors: Luchang Zhu; Randall J Olsen; Stephen B Beres; Matthew Ojeda Saavedra; Samantha L Kubiak; Concepcion C Cantu; Leslie Jenkins; Andrew S Waller; Zhizeng Sun; Timothy Palzkill; Adeline R Porter; Frank R DeLeo; James M Musser Journal: JCI Insight Date: 2020-06-04
Authors: Martina Sanderson-Smith; David M P De Oliveira; Julien Guglielmini; David J McMillan; Therese Vu; Jessica K Holien; Anna Henningham; Andrew C Steer; Debra E Bessen; James B Dale; Nigel Curtis; Bernard W Beall; Mark J Walker; Michael W Parker; Jonathan R Carapetis; Laurence Van Melderen; Kadaba S Sriprakash; Pierre R Smeesters Journal: J Infect Dis Date: 2014-05-05 Impact factor: 5.226
Authors: Shannon E Niedermeyer; Thomas A Penfound; Claudia Hohn; Yi Li; Ramin Homayouni; Jingnan Zhao; James B Dale Journal: Clin Vaccine Immunol Date: 2014-07-30